Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
6 stopped studies mapped to Myxoid Liposarcoma and descendants · 83% state a reason
Over the 6 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03670069 | Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas | Phase 1 | terminated | Sep 13, 2018 | Fred Hutchinson Cancer Center | The study was terminated early with 27 out of 28 planned subjects enrolled. This decision was… | Enrollment / accrual |
| NCT03399448 | NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | Phase 1 | terminated | Jan 16, 2018 | University of Pennsylvania | Sponsor has terminated trial to pursue other targets. | Other (stated, no rule matched) |
| NCT02609984 | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab… | Phase 2 | terminated | Nov 20, 2015 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | This study did not meet the efficacy objective | Efficacy / futility |
| NCT03397186 | Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma | Phase 2 | withdrawn | Jan 11, 2018 | Fred Hutchinson Cancer Center | Administrative | Other (stated, no rule matched) |
| NCT01957709 | Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma | Early Phase 1 | terminated | Oct 8, 2013 | Fred Hutchinson Cancer Center | Enough samples were collected for data analysis. | Other (stated, no rule matched) |
| NCT02059850 | NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced… | Phase 1 | withdrawn | Feb 11, 2014 | Fred Hutchinson Cancer Center | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated May 8, 2024source: clinicaltrials